Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults

Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes

(2010) J. M. Gaziano et al.   DIABETES CARE

Bromocriptine: old drug, new formulation and new indication

(2010) R. I. G. Holt et al.   DIABETES OBESITY & METABOLISM

Weight Gain Is Associated with Reduced Striatal Response to Palatable Food

(2010) E. Stice et al.   JOURNAL OF NEUROSCIENCE

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

(2010) Frank L Greenway et al.   LANCET

BMI and Metabolic Profile in Patients With Prolactinoma Before and After Treatment With Dopamine Agonists

(2010) Cintia M. dos Santos Silva et al.   Obesity

Reduced accumbens dopamine in Sprague–Dawley rats prone to overeating a fat-rich diet

(2010) Pedro Rada et al.   PHYSIOLOGY & BEHAVIOR

Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy

(2010) Katarina Berinder et al.   Pituitary

Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes

(2010) Via   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

The effects of hyperprolactinemia on bone and fat

(2008) Amal Shibli-Rahhal et al.   Pituitary

Induction of Central Leptin Resistance in Hyperphagic Pseudopregnant Rats by Chronic Prolactin Infusion

(2007) Rachael A. Augustine et al.   ENDOCRINOLOGY